Skip to main content
Premium Trial:

Request an Annual Quote

Fluxion, Harvard Bioscience Ink Distribution Deal

NEW YORK (GenomeWeb) – Fluxion Biosciences announced today that it has signed a distribution agreement for its BioFlux and IonFlux cellular analysis platforms with Harvard Bioscience.

BioFlux enables automated, high-throughput studies of cell-cell interactions, while microfluidics-based IonFlux is designed for ion channel research and drug discovery. Under the terms of the deal, Harvard Bioscience will offer the platforms to its customers in North America. Additional terms were not disclosed.

"IonFlux is a perfect fit with our other electrophysiology products, and extends our capabilities to high-throughput automated analysis," John Battista, North American sales director for electrophysiology products at Harvard Bioscience, said in a statement. "Similarly, the BioFlux system is a natural extension of our well-established Warner Instruments flow cell portfolio, permitting higher-throughput, microfluidic processing of eukaryotic and bacterial assays under flow."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.